Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.
The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.
The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predicto
The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting
The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.
The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo
Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.
CPL’116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase a
The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite
The ORCA-3 trial confirms cytisinicline’s efficacy and safety for smoking cessation at 6 and 12 weeks, showing sustained abstinence and reduced nicotine craving up to 24 weeks.
A large randomized clinical trial demonstrates that pulmonary rehabilitation using minimal equipment is noninferior to gym-based programs with specialist equipment for improving exercise capacity and quality of life in chronic respiratory d
This trial assessed the additive effects of low-dose transdermal estrogen replacement therapy combined with resistance exercise in women aged 65+ with knee osteoarthritis, finding no overall significant benefit but suggesting potential impr
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
The SAPPHIRE phase 3 trial found that adding apitegromab to nusinersen or risdiplam produced a small but statistically significant improvement in motor function in children aged 2–12, with a safety profile similar to placebo.
A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especial
Inhaled molgramostim, a recombinant human GM-CSF, significantly improves lung gas transfer and quality of life in autoimmune pulmonary alveolar proteinosis, with safety comparable to placebo.
A randomized clinical trial found that exenatide infusion during and after cardiopulmonary bypass did not reduce death or major organ failure in low-risk patients undergoing coronary artery bypass grafting or aortic valve replacement.
A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.